Risk factors

Valhi relies heavily on the TiO2 chemicals segment, component manufacturing, and Nevada real estate development.

Xeris Biopharma faces concentrated customer risk with four accounts generating over ninety percent of gross product revenue.

Xtant Medical operates with a history of net losses and a deficit of $259.5 million as of December 31, 2024. The company depends heavily on independent sales agents, tissue donors, and its Belgrade, Montana manufacturing facility. Growth relies on four key initiatives, strategic acquisitions, and compliance with complex FDA medical device and biologics regulations.

Clinical-stage biotechnology company dependent on the development of BET inhibitor product candidates repibresib gel and VYN202. Accumulated deficit of $731.2 million with net losses of $39.8 million in 2024. Subject to baby shelf rules limiting capital raising under Form S-3.

Arizona regulation and rate recovery dominate the risk section, especially ACC approval and customer cost recovery.

Service reliability, scaling Salesforce’s customer infrastructure, and integrating acquisitions are central operational risks.

International sales, manufacturing, and supply chains expose operations to global economic and political volatility.

High reliance on five major OEMs representing 58 percent of equipment and aftermarket parts purchases in 2024.

Amplify Energy relies heavily on variable-rate credit facilities and commodity hedging to offset volatility in oil and gas prices. Operations face concentrated geographic risks, customer concentration, and stringent regulatory compliance burdens across multiple jurisdictions. Environmental regulations and water disposal access pose ongoing threats to drilling and production feasibility.

Amerant Bancorp faces heavy exposure to commercial real estate loans, interest rate shifts, and geographic concentration in Florida. Significant reliance on Venezuelan resident deposits creates unique geopolitical and operational vulnerability for the bank.

Company faces substantial accumulated deficits totaling $363.2 million and relies heavily on a single customer and licensed products like Sympazan, Suboxone, and Azstarys. Operations depend on complex manufacturing processes with limited suppliers for thin film foil and API. Capital needs require ongoing financing and debt management, including $45.0 million in 13.5% Notes.

Arq, Inc. faces high execution risks scaling its Red River Plant and GAC Facility following the Arq Acquisition. The company carries $13.8 million in debt under its Revolving Credit Facility and a $10.0 million CTB Loan. Concentration is high, with five customers generating 45% of 2024 revenue.